Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Orlando, Florida 32809


Purpose:

This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of TD-4208.


Criteria:

Inclusion Criteria: - For hepatic impairment group: Subject has moderate hepatic impairment (Child Pugh B) - For normal hepatic function group: Subject is in good health Exclusion Criteria: - Women who are pregnant, lactating, breastfeeding, or planning to become pregnant during the study. - Subject has received an investigational drug (or medical device) within 30 days - Subject who, for any reason, is deemed by the investigator to be inappropriate for this study; or has any condition that would confound or interfere with the evaluation of the safety, tolerability, or PK of the investigational drug; or is unable to comply with the study protocol.


NCT ID:

NCT02581592


Primary Contact:

Study Director
Medical Monitor
Theravance Biopharma


Backup Contact:

N/A


Location Contact:

Orlando, Florida 32809
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.